• DNA repair: Locating and severing lethal

    From ScienceDaily@1337:3/111 to All on Thu Aug 27 21:30:36 2020
    DNA repair: Locating and severing lethal links

    Date:
    August 27, 2020
    Source:
    Ludwig-Maximilians-Universita"t Mu"nchen
    Summary:
    Covalent cross-links between proteins and DNA are among the most
    hazardous types of DNA damage. Researchers have now characterized
    an enzyme that breaks such bonds, and elucidated how it specifically
    recognizes sites of damage.



    FULL STORY ========================================================================== Chemical lesions in the genetic material DNA can have catastrophic
    consequences for cells, and even for the organism concerned. This
    explains why the efficient identification and rapid repair of DNA damage
    is vital for survival. DNA- protein crosslinks (DPCs), which are formed
    when proteins are adventitiously attached to DNA, are particularly
    harmful. DPCs are removed by the action of a dedicated enzyme --
    the protease SPRTN -- which cleaves the bond between the protein and
    the DNA. Up to now, how SPRTN recognizes such crosslinks, which can
    differ significantly in structure, has remained unclear. Now a team led
    by Professor Julian Stingele (LMU Gene Center), in cooperation with
    Professor Michael Sattler (Helmholtz Zentrum Mu"nchen and Technical
    University of Munich), has shown that the enzyme utilizes a modular
    recognition mechanism to detect such sites, such that it is activated
    only under highly specific conditions. The new findings appear in the
    journal Molecular Cell.


    ==========================================================================
    DPCs can be created by interactions with highly reactive products
    of normal metabolism or with synthetic chemotherapeutic agents. These
    lesions are extremely toxic because they block the replication of DNA --
    and therefore inhibit cell division. Timely and effective repair of these crosslinks by SPRTN is crucial for cell viability and the suppression
    of tumorigenesis. In humans, mutations that reduce the activity of the
    enzyme are associated with a high incidence of liver cancer in early life
    and markedly accelerate the aging process. "SPRTN has a difficult job
    to do because, depending on the protein and the DNA subunit involved,
    the structure of the crosslink can vary widely. So the enzyme has to be
    able to identify many different structures as aberrant," explains Hannah Reinking, first author of the study. "We therefore asked ourselves what
    sorts of properties a DPC should have in order to be recognized and
    cleaved." To answer this question, Reinking and colleagues constructed
    model substrates consisting of proteins attached to defined positions
    within DNA strands, and examined whether the SPRTN protease could repair
    them in the test-tube. This approach revealed that SPRTN interacts with structures that are frequently found in the vicinity of DPCs. With the
    aid of nuclear magnetic resonance spectroscopy, they went on to show
    that SPRTN contains two recognition domains.

    One binds to double-stranded, and the other to single-stranded DNA. "So
    the protein uses a modular system for substrate recognition. Only
    when both domains are engaged is the enzyme active -- and DNA in which double-stranded and single-stranded regions occur in close proximity is
    often found in the vicinity of crosslinks," says Stingele.

    These results are also of clinical relevance. The action of many chemotherapeutic drugs depends on their ability to form crosslinks
    with DNA.

    Since tumor cells divide more frequently than non-malignant cells, they
    are particularly sensitive to this type of DNA damage. DNA repair enzymes
    like SPRTN are therefore of great interest as potential drug targets
    for use in the context of personalized cancer therapies, and agents
    that specifically inhibit the protease could eventually be employed to
    boost the efficacy of chemotherapy. "Our work now makes it possible to conceptualize such therapeutic strategies," says Stingele.


    ========================================================================== Story Source: Materials provided by
    Ludwig-Maximilians-Universita"t_Mu"nchen. Note: Content may be edited
    for style and length.


    ========================================================================== Journal Reference:
    1. Hannah K. Reinking, Hyun-Seo Kang, Maximilian J. Go"tz, Hao-Yi
    Li, Anja
    Kieser, Shubo Zhao, Aleida C. Acampora, Pedro Weickert, Evelyn
    Fessler, Lucas T. Jae, Michael Sattler, Julian Stingele. DNA
    Structure-Specific Cleavage of DNA-Protein Crosslinks by the SPRTN
    Protease. Molecular Cell, 2020; DOI: 10.1016/j.molcel.2020.08.003 ==========================================================================

    Link to news story: https://www.sciencedaily.com/releases/2020/08/200827141339.htm

    --- up 3 days, 6 hours, 50 minutes
    * Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1337:3/111)